Global Tuberculosis (TB) Market Spotlight 2019-2027: GlaxoSmithKline Leads Industry Sponsors with the Highest Overall Number of Clinical Trials - ResearchAndMarkets.com

DUBLIN--()--The "Market Spotlight: Tuberculosis (TB)" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

Key Takeaways

  • It is estimated that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.
  • Approved drugs in the TB space focus on a variety of targets. The majority of these drugs are administered via the oral route, with the remainder being topical and intravenous formulations.
  • The greatest proportion of industry-sponsored drugs in active clinical development for TB are in Phase II. Therapies in mid-to-late-stage development for TB focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being tested in intramuscular and intradermal formulations.
  • High-impact upcoming events for drugs in the TB space comprise CHMP supplemental filing results for Sirturo, CHMP opinion for Pretomanid, and topline Phase II trial results for GSK3036656.
  • The overall likelihood of approval of a Phase I antibacterial, mycobacterial, or fungal asset is 25%, and the average probability a drug advances from Phase III is 64.2%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.1 years in the overall infectious disease space.
  • There have been 23 licensing and asset acquisition deals involving TB drugs during 2014-19. The largest deal was the $74.5m transaction agreement in 2018 between Evotec and Sanofi, pursuant to which Evotec will integrate Sanofi's infectious disease unit into its organization and in-license the majority of Sanofi's infectious disease research portfolio, including TB.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for TB have been in the early and midphases of development, with 75% of trials in Phase I-II, and only 25% in Phase III-IV.
  • South Africa has a substantial lead in the number of TB clinical trials globally. The UK leads the major EU markets, while China has the top spot in Asia.
  • Clinical trial activity in the TB space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for TB, with 17 trials.
  • GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for TB.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient subtypes
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Anti-tuberculosis drugs
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Pretomanid for tuberculosis (June 6, 2019)

Pretomanid for tuberculosis (June 4, 2019)

Pretomanid for tuberculosis (April 18, 2019)

Pretomanid for tuberculosis (October 26, 2018)

M72/AS01E for tuberculosis (September 25, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions

Pretomanid Gets Panel Endorsement As Part Of Regimen, Not Individual Molecule, For Treatment-Resistant Tuberculosis

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

BioNTech Gets Gates Foundation Funding For HIV, TB Drug Discovery

Deals Shaping The Medical Industry, December 2018

Deals Shaping The Medical Industry, October 2018

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

BIBLIOGRAPHY

Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/9lb60r

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900